Navigation Links
ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
Date:3/5/2010

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' discovery and development
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
2. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
3. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
4. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
5. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
6. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
7. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
8. Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
9. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), a company ... and physician groups, today reported financial results for the ... "In the second quarter of 2015, Semler reported continued ... quarter over quarter revenue growth of 8%, and quarter ... units of 18%," said Doug Murphy-Chutorian, M.D., chief executive ...
(Date:7/31/2015)... N.J. and SAN DIEGO ... that its parent company Eisai Co., Ltd. (Headquarters: ... Naito , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Dr. Helen Torley , "NASDAQ: HALO") have signed ... (brand name: Halaven ® , "eribulin") in combination with ...
(Date:7/31/2015)... 31, 2015  Xencor, Inc. (NASDAQ: XNCR ), ... the treatment of autoimmune diseases, asthma and allergic diseases, ... S. Hata to its board of directors. ... corporate development is a tremendous asset to our board," ... executive officer of Xencor. "Xencor faces a range of ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... (NYSE Amex: PIP ), a biodefense company ... today that Eric I. Richman, President and Chief Executive ... Healthcare Conference being held November 29-30, 2011.  ... in one-on-one meetings at the conference.Event : , ...
... 28, 2011  CIVCO Medical Solutions is introducing RAD-GUIDE, ... at RSNA 2011. RAD-GUIDE allows physicians a method ... visualizing and adjusting planned punctures prior to needle ... to translating our expertise in ultrasound needle guidance ...
Cached Medicine Technology:PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2CIVCO Enters CT Needle Guidance Market with RAD-GUIDE™ Launch 2
(Date:7/30/2015)... ... July 31, 2015 , ... ... By 50% or More, **Presented by FDAnews and Ginette M. Collazo, Inc.**, Sept. ... 15 year veteran of helping drug, biologic and device firms reduce manufacturing errors ...
(Date:7/30/2015)... FL (PRWEB) , ... July 31, 2015 , ... On ... first meeting in Manatee county to discuss plausible solutions for controlling the heroin outbreak. ... the event of an overdose is largely perpetuating the heroin crisis in North Florida. ...
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent Marketing, a ... app invention that can help people during emergencies. , "The worldwide mobile health ... Creative Director of World Patent Marketing. "Currently, there are about 97,000 mobile health ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... BioPharma, Inc. are pleased to announce that data standards for clinical research in ... on the CDISC website . These three Therapeutic Area (TA) standards were ...
(Date:7/30/2015)... ... , ... In an effort to provide the twenty four hour continuous care ... his practice. , The decision will also allow him to spend more time in ... his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2
... Doctors use diagnostic sonography or ultrasound to visualise organs ... researcher Koos Huijssen has developed a computer model that ... ultrasound instruments. The computer model is capable of processing ... both a PC and a parallel supercomputer. Erasmus University ...
... American Society of,Hematology (ASH), the world,s largest professional ... its Executive Committee, the,governing body of the organization. ... 2009., J. Evan Sadler, MD, PhD, will ... successive terms as president-elect and president. Charles,Abrams, MD, ...
... Nov. 4 Election Day statement by,SEIU President Andy ... Tacoma, Washington, who lost,her home and all her savings ... -- will vote today., "Samara Knight -- a ... can,t afford her mortgage payments and the,medication her son ...
... HOLLYWOOD, Calif., Nov. 4 IPC The,Hospitalist Company, Inc. ... practice company, announced today that Adam D. Singer,Chief Executive ... scheduled to present on Wednesday, November 12, 2008 at ... AZ., Event: 2008 Annual Credit Suisse ...
... Allied Minds funds research to reduce,wrinkles by developing ... a seed investment firm specializing in early stage ... Berkeley National,Laboratory through creation of start-up company, ProGDerm, ... Mina Bissell will develop a,technology based on modulation ...
... Will Sell Programming Kit and Software ,Separately From its Hearing Aids ... ... November 4, 2008 -- America Hears, Inc. , the leading ... improved version of its hearing-aid programming software, Virtual Office, and announced ...
Cached Medicine News:Health News:New Leadership Elected to the American Society of Hematology 2Health News:Today We Must Be the Change We Need 2Health News:IPC The Hospitalist Company, Inc. to Present at the 2008 Annual Credit Suisse Health Care Conference 2Health News:New Skin Rejuvenation Discovery Receives Commercial Backing 2Health News:America Hears Introduces New and Improved Hearing-Aid Programming Software 2Health News:America Hears Introduces New and Improved Hearing-Aid Programming Software 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: